NCCN Strives to Control Cost of Cancer Drugs With New Evaluation Framework

Tony Hagen @oncobiz
Published: Tuesday, Aug 25, 2015
Robert Carlson, MD, CEO of the NCCN

Robert Carlson, MD

Key Takeaways
  • NCCN Guidelines for Chronic Myelogenous Leukemia and Multiple Myeloma will be the first to incorporate cost elements.
  • The NCCN also plans to incorporate cost into the existing NCCN Chemotherapy Order Templates.
  • The payer Anthem says drug valuation tools fall short of need, but are an “extremely positive step.”
  • ASCO’s drug valuation tool will supplement the CancerLinQ patient information portal to more broadly inform treatment decisions.
As cancer drugs soar in price, the National Comprehensive Cancer Network (NCCN) is introducing cost as a measure of the overall value of a therapy, following the trail of ASCO and a doctor from Memorial Sloan Kettering Cancer Center in attempting to put a lid on drug inflation.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication